The New York Academy of Medicine
15
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
27%
4 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
ActionHealthNYC Research Study
Role: collaborator
The LIFT-ECHO Last Mile Project
Role: collaborator
Impact of Medicaid Health Home on Patients With Diabetes in New York City
Role: collaborator
Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations
Role: collaborator
Buprenorphine and Integrated HIV Care
Role: collaborator
PowerUp for Health: A Diabetes Prevention Program for Men
Role: collaborator
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
Role: collaborator
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
Role: collaborator
Project UNITY - HIV Risk Reduction and Vaccine Education Interventions
Role: collaborator
A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men
Role: collaborator
Integrating Buprenorphine Into the SFGH AIDS Program
Role: collaborator
The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration
Role: collaborator
Buprenorphine and Integrated HIV Care Evaluation
Role: lead
Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA
Role: lead
Rapid Vaccination of Hard-To-Reach Populations
Role: lead
All 15 trials loaded